ArticleFrontiers in epidemiology2022
Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019.
Article in Frontiers in epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Changes over time in hallucinogen-related emergency department visits in Ontario, Canada.Addiction (Abingdon, England) · 2026Article
- Hallucinogen use in the United States, 2021-2023: Diverging trends and subgroup patterns.Drug and alcohol dependence reports · 2026Article
- The Relationship Between Psychedelic Use and Positive Adult Development in Emerging Adulthood: An Integrative Review.Brain and behavior · 2025Review
- Population-based estimates of different dosage types of psychedelic use across socio-demographic groups in Germany.Scientific reports · 2025Article
- Association of Hallucinogen Use With Psychosocial Outcomes: Secondary Analysis of the Spinal Cord Injury Model Systems Database.Topics in spinal cord injury rehabilitation · 2025Article
- Ethnoracial inclusion in clinical trials of psychedelics: a systematic review.EClinicalMedicine · 2024Review
- Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020.Journal of psychopharmacology (Oxford, England) · 2023Article
- Prevalence and Correlates of Lifetime Ecstasy/MDMA Use Among Asian American and Pacific Islander Adult Populations in the United States, 2015-2020.Journal of psychoactive drugsArticle
- Psychedelic Microdosing among Young Adults from Southern California.Journal of psychoactive drugsArticle
- Prevalence and Correlates of Past Year Ecstasy/MDMA Use in the United States.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The current study is one of the first to examine race, ethnic, and sex differences in the prevalence of and trends in hallucinogen use among lifetime users in the United States. Methods: Data came from the 2015-2019 National Survey on Drug Use and Health and included respondent's reporting ever-using hallucinogens ( Results: Highest prevalence of past year hallucinogen use was among Asian females (35.06%), which was two-or-more times larger than prevalence of past year use among White males/females and Native American males. More than half of White males/females, Multiracial males, and Hispanic males reported had ever-used psilocybin or LSD, whereas less than one-quarter of Black males/females reported lifetime psilocybin use, and less than a third of Black females reported lifetime LSD use. Native American males had the lowest prevalence of lifetime MDMA use (17.62-33.30%) but had the highest lifetime prevalence of peyote use (40.37-53.24%). Pacific Islander males had the highest prevalence of lifetime mescaline use (28.27%), and lifetime DMT use was highest among Pacific Islander males/females (15.68-38.58%). Black, Asian, and Multiracial people had greater odds of past-year (ORs = 1.20-2.02; Conclusions: These findings should inform public health initiatives regarding potential benefits and risks of hallucinogen use among racial/ethnic groups and women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.